Navigation Links
Novel combination therapy shuts down escape route, killing glioblastoma tumor cells
Date:2/26/2013

February 26, 2013, New York, N.Y. and San Diego, Calif. Glioblastoma, the most common and lethal form of brain tumor in adults, is challenging to treat because the tumors rapidly become resistant to therapy. As cancer researchers are learning more about the causes of tumor cell growth and drug resistance, they are discovering molecular pathways that might lead to new targeted therapies to potentially treat this deadly cancer.

Scientists at the Ludwig Institute for Cancer Research in San Diego worked collaboratively across the laboratories of Drs. Paul Mischel, Web Cavenee and Frank Furnari to investigate one such molecular pathway called the mammalian target of rapamycin or mTOR. This signaling pathway is hyperactivated in close to 90 percent of glioblastomas and plays a critical role in regulating tumor growth and survival. Therapies that inhibit mTOR signaling are under investigation as drug development targets, but results to date have been disappointing: mTOR inhibitors halt the growth but fail to kill the tumor cells.

A study published this week in the Proceedings of the National Academy of Sciences uncovers an unexpected but important molecular mechanism of mTOR inhibitor resistance and identifies a novel drug combination that reverses this resistance.

The story begins with a closer look at a gene-encoded protein called promyleocytic leukemia gene or PML. The study investigators explored the role of PML in causing resistance to mTOR inhibitor treatment. They found that when glioblastoma patients are treated with drugs that target the mTOR pathway, the levels of PML rise dramatically. Further, they showed that PML upregulation made the tumor cells resistant to mTOR inhibitors, and that if they suppressed the ability of the tumor cells to upregulate the PML protein, the tumor cells died in response to the mTOR inhibitor therapy.

"When we looked at cells in in vivo models and patients treated in the clinic, i
'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers discover novel therapy for Crohns disease
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Notre Dame researchers using novel method to combat malaria drug resistance
4. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
5. Key proteins newly discovered form and function may provide novel cancer treatment target
6. Novel discovery by NUS scientists paves the way for more effective treatment of cancers
7. London researchers discover novel mechanism involved in key immune response
8. Mexican rock heroes trial novel green trading system
9. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
10. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
11. Novel nano-structures to realize hydrogens energy potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... by Yale biologists, of the effects of 1997 El ... the Galpagos Islands, emphasizes the importance of studying populations ... and biological factors make specific populations more vulnerable than ... events provide an ideal system to study the impact ...
... describes hundreds of well-known and respected physicians, scientists, ... or advocated for homeopathic medicine. Eleven U.S. ... Charles Kettering, and C. Everett Koop are among ... benefited from homeopathy. Perhaps most surprisingly is the ...
... CHAMPAIGN, Ill. Using computer simulations, researchers at the University ... driving the molecule back and forth through a nanopore capacitor ... device that would read human genomes quickly and affordably., Being ... (which is the price most insurance companies are willing to ...
Cached Biology News:Global climate change: The impact of El Nio on Galpagos marine iguanas 2The surprising story of Charles Darwin and his homeopathic doctor 2The surprising story of Charles Darwin and his homeopathic doctor 3New technique could dramatically lower costs of DNA sequencing 2
(Date:11/26/2014)... 2014 The North America Thermal ... market for detailed analysis of the growth trends ... reach $616.3 million by 2018, growing at a ... Browse through the TOC of the North America ... idea of the in-depth analysis and industry segmentation ...
(Date:11/26/2014)... , Nov. 26, 2014 The announced ... indicate the company is looking to expand in non-healthcare ... sales.  The healthcare market research firm says that  Siemens ... Kalorama Information,s biennial survey of the IVD market , ... any change in its composition would likely affect IVD ...
(Date:11/26/2014)... The Alliance for Safe Biologic ... European physicians at the "1 ST EuropaBio ... at the Spanish Ministry of Health, Social Services ... the Spanish Bioindustry Association (ASEBIO), included regulators from ... oncology and rheumatology societies, representatives from a hospital ...
(Date:11/26/2014)... November 26, 2014 The ETC ... award-winning technology innovation centers, announced today that applications ... on December 1st. “Do you have a big ... I want to know about it. AccelerateBaltimore helps ... to product in just 13 weeks.” Interested ...
Breaking Biology Technology:The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2ASBM Presents European Physicians Survey at Spanish Ministry of Health 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3
... Centers,of America, Inc. (Navitas), the market leader in ... to announce the,appointment of Dean H. Gesme, Jr., ... to currently providing care as a medical oncologist ... as the Past-Chair of the,National Coalition for Cancer ...
... Oct. 17 Monsanto Company (NYSE:,MON) today announced ... president and chief executive officer, and Robb Fraley, ... stock trading,plans in accordance with Rule 10b5-1 of ... plans, the Monsanto executives have directed brokers in ...
... Calif. and OSAKA, Japan, Oct. 17 Affymax,Inc. ... Limited (TSE: 4502),today announced that they have been ... Licensing Executives Society of the U.S. and Canada ... commercialize,Affymax,s lead product candidate, Hematide(TM), for the treatment ...
Cached Biology Technology:Navitas Names Dr. Dean Gesme as Medical Director 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 3
... Invitrogens EvoQuest Services are ... prevail in the current competitive ... proprietary techniques to express, purify, ... your needs: Structure/Function Studies, Activity ...
... Standard Tray (3 per pack), 1. ... and blot processing.Automated staining of Coomassie ... and nucleic acid analysis.Prepares blots for ... detection.Programmable control of protocol, solution, volume, ...
... High quality kits and reagents ... give consistent and reliable 2-D ... up samples from contaminants.Efficiently dialyze ... protein for first-dimension isoelectric focusing.Reagents ...
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: